Ac Immune Sa

Teva Pharmaceutical Industries Limited

Life Molecular Imaging Sa

Life Molecular Imaging Limited

Emanuele Gabellieri

Sreenivasachary Nampally

Heiko Kroth

Jerome Molette

Heribert Schmitt-Willich

Mathias Berndt

Jérôme Molette

Hanno Schieferstein

Vincent Darmency

Iolanda Micco

Georg C Terstappen

Matteo Magnani

Chiara Caramelli

Cesare Federico

Wolfgang Froestl

Felix Oden

Andre Müller

Jérome Molette

Cedric Boudou

Pascal André René Benderitter

Andre Mueller

Johnny Castillo Melean

Marion Zerna

Andre Muller

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

Compounds for the treatment or alleviation of disorders associated with Tau aggregates

Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates

The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (&#x3b1;-synuclein, A-synuclein, aSynuclein, A-syn, &#x3b1;-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

Bicyclic compounds for diagnosis and therapy

The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.

S1P3 antagonists

The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.

Compounds for imaging Tau protein aggregates

The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Alzheimer's disease. Precursors for the preparation of the compounds according to the present invention are also provided.

Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins

Growing community of inventors

Lausanne, Switzerland

Emanuele Gabellieri